Federal Drug Rescheduling Reform: How Congress Could Change Cannabis Classification

Executive Summary

A new congressional bill introduced in June 2026 proposes a fundamental restructuring of federal drug scheduling by allowing states to trigger mandatory federal reclassification reviews. The legislation, filed by a Democratic congressman, would transform the Controlled Substances Act framework that has governed drug policy since 1970 by creating a bottom-up mechanism where state-level reforms could compel federal action. Under the proposed system, when a threshold number of states change their classification of a substance like marijuana or psilocybin, the Drug Enforcement Administration would be required to initiate a formal rescheduling process. This represents a dramatic departure from the current top-down federal system where the DEA and Food and Drug Administration control scheduling decisions independent of state actions. The bill arrives as 38 states have legalized medical cannabis, 24 have approved adult-use programs, and several states have decriminalized psychedelics—creating a widening gap between state and federal drug policy that has generated legal confusion, banking obstacles, and enforcement inconsistencies affecting millions of patients and thousands of businesses.

Why This Matters

The proposed legislation addresses a core tension in American federalism where state-legal cannabis businesses operate in violation of federal law, affecting $30 billion in annual sales and 400,000 jobs. The current scheduling system places marijuana in Schedule I of the Controlled Substances Act alongside heroin, defining it as having no accepted medical use and high abuse potential—a classification that contradicts state medical programs serving over 7 million registered patients nationwide. This federal-state conflict creates cascading consequences. Cannabis businesses cannot access traditional banking services, forcing many to operate cash-only. Internal Revenue Code Section 280E prohibits these businesses from deducting ordinary expenses, resulting in effective tax rates exceeding 70 percent. Researchers face regulatory barriers to studying substances that remain federally prohibited despite state legalization. Interstate commerce remains illegal, preventing efficient supply chains and forcing each state to maintain isolated markets. For multi-state operators, the current system imposes duplicative compliance costs across 38 different regulatory frameworks while maintaining federal criminal liability. For patients, Schedule I status restricts physician recommendations in states without explicit medical programs and creates employment discrimination risks despite state protections. Veterans receiving care through the Department of Veterans Affairs cannot access medical cannabis recommendations due to federal restrictions, even in states where programs exist. The bill's state-trigger mechanism would shift power from federal agencies to state legislatures and voters, potentially accelerating reforms that have moved slowly through traditional DEA processes. The pending marijuana rescheduling to Schedule III, announced in 2024 but not yet finalized, has taken over two years—illustrating the glacial pace of current procedures.

Background and History of Federal Drug Scheduling

The Controlled Substances Act, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, established the five-schedule classification system that governs federal drug policy today. President Richard Nixon signed the legislation on October 27, 1970, consolidating previous drug laws into a unified framework administered by the newly created Drug Enforcement Administration (which succeeded the Bureau of Narcotics and Dangerous Drugs in 1973).

The Original Five-Schedule Framework

The CSA created five schedules under 21 U.S.C. § 812, each with distinct criteria. Schedule I substances must have high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision. Schedule II through V substances have accepted medical uses but decreasing potential for abuse and dependence. Congress initially placed marijuana in Schedule I as a temporary measure, directing the National Commission on Marihuana and Drug Abuse to study the issue—a commission that recommended decriminalization in 1972, advice Congress ignored.

Early Rescheduling Attempts: 1972-1988

The first petition to reschedule marijuana came in 1972 from the National Organization for the Reform of Marijuana Laws. The petition languished for 16 years before DEA Administrative Law Judge Francis Young ruled in 1988 that marijuana should be rescheduled to Schedule II, stating "marijuana, in its natural form, is one of the safest therapeutically active substances known to man." DEA Administrator John Lawn rejected Young's recommendation, establishing a pattern of agency resistance to rescheduling that would persist for decades.

State Medical Programs Begin: 1996-2012

California voters approved Proposition 215 in November 1996, creating the first state medical cannabis program and initiating the federal-state conflict that continues today. The Clinton administration responded with threats to prosecute physicians who recommended cannabis, leading to the Conant v. Walters litigation that ultimately protected physician speech rights. Alaska, Oregon, and Washington followed with medical programs in 1998, and Maine joined in 1999. The George W. Bush administration escalated federal enforcement despite state laws, conducting high-profile raids on medical dispensaries in California. The Supreme Court ruled in Gonzales v. Raich (2005) that Congress could prohibit locally grown cannabis under the Commerce Clause even when state law permitted it, though the decision did not invalidate state programs. By 2012, 18 states had enacted medical cannabis laws, setting the stage for adult-use legalization.

Adult-Use Legalization: 2012-Present

Colorado and Washington voters approved adult-use legalization in November 2012, with sales beginning in 2014. The Obama administration responded with the Cole Memorandum in August 2013, directing federal prosecutors to deprioritize cannabis enforcement in states with robust regulatory systems. Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, though practical enforcement remained limited. As of June 2026, 24 states have legalized adult-use cannabis, with Ohio becoming the most recent addition through a November 2023 ballot measure that took effect in 2024.

The 2024 Rescheduling Announcement

In May 2024, the DEA announced its intent to reschedule marijuana from Schedule I to Schedule III, marking the most significant federal policy shift in cannabis history. The proposal followed a Department of Health and Human Services recommendation in August 2023 based on a Food and Drug Administration review. The rescheduling would acknowledge accepted medical use and lower abuse potential while maintaining federal prohibition—cannabis would remain a controlled substance, but Schedule III status would eliminate 280E tax penalties and ease research restrictions. The DEA published a Notice of Proposed Rulemaking and opened a public comment period that drew over 43,000 submissions. As of June 2026, the final rule has not been published, with the process stalled in administrative review.

Psychedelic Reform Movement: 2020-2026

Oregon voters approved Measure 109 in November 2020, creating the first state-regulated psilocybin therapy program, which launched in 2023. Colorado followed with Proposition 122 in November 2022, decriminalizing psilocybin and establishing a regulated access program. California, Massachusetts, and Washington have seen local jurisdictions deprioritize enforcement of psychedelic possession. The federal government has shown no movement toward rescheduling psychedelics, which remain in Schedule I, despite growing research into therapeutic applications for PTSD, depression, and end-of-life anxiety.

Key Players in Federal Scheduling Policy

Drug Enforcement Administration

The DEA holds ultimate authority over scheduling decisions under 21 U.S.C. § 811, though it must request a scientific and medical evaluation from the Department of Health and Human Services. The agency has historically resisted cannabis rescheduling despite multiple petitions and judicial recommendations. DEA Administrator Anne Milgram, appointed in 2021, oversees the pending Schedule III rescheduling. The agency's Diversion Control Division manages the registration system for researchers and manufacturers of controlled substances, creating bottlenecks that have limited cannabis research for decades.

Food and Drug Administration

The FDA conducts the scientific and medical evaluation required for scheduling decisions, assessing abuse potential, pharmacological effects, and therapeutic value. The agency completed its marijuana review in August 2023, concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. FDA Commissioner Robert Califf has emphasized the need for clinical trials to establish specific medical indications, though Schedule I status has historically impeded such research. The agency approved Epidiolex, a CBD-based epilepsy treatment, in 2018, and synthetic THC products Marinol and Syndros for nausea and appetite stimulation.

Department of Health and Human Services

HHS provides binding scientific recommendations to the DEA on scheduling matters. Secretary Xavier Becerra transmitted the recommendation to reschedule marijuana to Schedule III in August 2023 following the FDA review. The department's National Institute on Drug Abuse controls the sole federal license to grow cannabis for research purposes, historically limiting supply to a single facility at the University of Mississippi—a monopoly that ended in 2021 when the DEA approved additional growers, though production remains limited.

Congress and Legislative Proposals

The June 2026 bill represents the latest in a series of congressional attempts to reform federal cannabis policy. Previous legislation includes the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which passed the House in 2020 and 2022 but stalled in the Senate, and the Cannabis Administration and Opportunity Act introduced by Senate Majority Leader Chuck Schumer. The SAFE Banking Act, which would protect financial institutions serving cannabis businesses, has passed the House seven times but has not advanced in the Senate. The new state-trigger bill introduces a novel federalism approach not present in previous proposals.

State Governments and Regulatory Agencies

State cannabis control boards in California, Colorado, Washington, and other legalized jurisdictions have developed sophisticated regulatory frameworks that operate in tension with federal prohibition. California's Department of Cannabis Control oversees the largest legal market, with $5.3 billion in sales in 2024. These state agencies set testing standards, track inventory through seed-to-sale systems, collect excise taxes, and enforce compliance—functions that would typically involve federal oversight in other industries but remain state-only due to federal prohibition.

Industry and Advocacy Organizations

The National Cannabis Industry Association represents over 1,500 businesses and has lobbied extensively for federal reform. The U.S. Cannabis Council focuses on large multi-state operators. NORML, founded in 1970, advocates for legalization and has coordinated multiple rescheduling petitions. The Drug Policy Alliance and Marijuana Policy Project have funded state ballot initiatives. Americans for Safe Access focuses specifically on medical patient rights. These organizations have collectively spent over $50 million on federal lobbying since 2016.

Legal and Regulatory Framework

The Controlled Substances Act establishes the legal architecture for drug scheduling through 21 U.S.C. §§ 801-904, with scheduling criteria defined in 21 U.S.C. § 812 and procedures in 21 U.S.C. § 811. The Attorney General, acting through the DEA, may initiate scheduling proceedings or respond to petitions from interested parties. The process requires an eight-factor analysis including the substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance.

Current Rescheduling Procedures

When the DEA receives a rescheduling petition, it requests a scientific and medical evaluation from HHS under 21 U.S.C. § 811(b). The HHS recommendation binds the DEA on scientific and medical matters—if HHS finds a substance has accepted medical use, the DEA cannot place it in Schedule I. However, the DEA retains authority over the final scheduling decision based on abuse potential and enforcement considerations. The agency must publish a Notice of Proposed Rulemaking in the Federal Register, accept public comments, and may hold hearings before issuing a final rule. This process has historically taken years or decades.

Administrative Procedure Act Requirements

Scheduling decisions constitute informal rulemaking under the Administrative Procedure Act, 5 U.S.C. § 553. Agencies must provide notice, accept comments, consider the record, and provide a reasoned explanation for their decision. Courts review final rules under the arbitrary and capricious standard of 5 U.S.C. § 706(2)(A), deferring to agency expertise but requiring rational connection between facts and conclusions. The pending marijuana rescheduling has generated over 43,000 comments that the DEA must review and address in its final rule.

Constitutional Federalism Tensions

The Tenth Amendment reserves powers not delegated to the federal government to the states, but the Supremacy Clause in Article VI establishes that federal law preempts conflicting state law. In Gonzales v. Raich, 545 U.S. 1 (2005), the Supreme Court held that Congress could prohibit intrastate cannabis cultivation under the Commerce Clause even where state law permitted it. However, the anti-commandeering doctrine from Printz v. United States, 521 U.S. 898 (1997), prevents the federal government from requiring states to enforce federal law. States can legalize cannabis under their own law, and the federal government cannot force state police to arrest cannabis users—but federal law continues to apply, and federal agents can make arrests. This creates the current system where state-legal cannabis businesses violate federal law but face minimal federal enforcement due to resource constraints and policy priorities. The proposed state-trigger legislation would formalize state influence over federal policy rather than maintaining parallel systems.

Banking and Tax Implications

Financial institutions operating under federal charters risk prosecution for money laundering under 18 U.S.C. § 1956 if they service cannabis businesses, as they would be handling proceeds of federal drug trafficking. The Financial Crimes Enforcement Network issued guidance in 2014 suggesting banks could serve cannabis businesses if they filed Suspicious Activity Reports, but most banks have declined due to legal uncertainty. Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, though they may deduct cost of goods sold. This provision would not apply to Schedule III substances, making the pending rescheduling financially significant even without legalization.

The New State-Trigger Proposal

The June 2026 bill would amend 21 U.S.C. § 811 to require the DEA to initiate rescheduling proceedings when a threshold number of states change their classification of a substance. While the full legislative text has not been published as of the bill's introduction, the proposal reportedly establishes a mechanism where state-level reforms automatically trigger federal review rather than requiring federal agencies to act independently.

Proposed Mechanism

The legislation would create a monitoring system where the DEA tracks state drug classifications. When states representing a specified percentage of the U.S. population—potentially 25 or 33 percent based on similar federalism proposals—enact laws removing a substance from their most restrictive category or legalizing medical or adult use, the DEA would face a mandatory deadline to publish a Notice of Proposed Rulemaking. This would eliminate the agency's current discretion to ignore state trends or delay action indefinitely.

Application to Current Substances

If enacted, the bill would immediately affect marijuana, as 38 states with medical programs represent over 70 percent of the U.S. population. The threshold would have been met years ago, potentially forcing rescheduling by 2018 or earlier. For psychedelics, Oregon and Colorado represent approximately 7 percent of the population, well below any likely threshold, though additional states are considering reforms. MDMA, currently in Schedule I, is under FDA review for PTSD treatment, with a decision expected in 2026—state-level reforms have not yet materialized but could follow federal therapeutic approval.

Procedural Safeguards and Limitations

The bill would not mandate a specific scheduling outcome, only that the DEA initiate the review process. The agency would still conduct the eight-factor analysis, request HHS scientific review, accept public comments, and issue a final rule based on the evidence. However, the mandatory trigger would prevent indefinite delay and force the agency to publicly justify maintaining a federal prohibition that contradicts widespread state practice. The legislation would likely include judicial review provisions allowing parties to sue if the DEA fails to meet deadlines.

State-by-State Cannabis Status

As of June 2026, 24 states have legalized adult-use cannabis, 38 have medical programs, and 13 maintain full prohibition. This patchwork creates the regulatory fragmentation that the new bill seeks to address.

Adult-Use Legal States

State	Legalization Date	Possession Limit	Home Cultivation	2024 Sales
California	January 2018	1 ounce	6 plants	$5.3 billion
Colorado	January 2014	1 ounce	6 plants	$1.6 billion
Washington	July 2014	1 ounce	Prohibited	$1.4 billion
Massachusetts	November 2018	1 ounce	6 plants	$1.8 billion
Illinois	January 2020	30 grams	5 plants (medical only)	$1.7 billion
Michigan	December 2019	2.5 ounces	12 plants	$3.0 billion
New York	March 2021 (sales began 2023)	3 ounces	6 plants (coming)	$1.2 billion
Ohio	December 2023	2.5 ounces	6 plants	$450 million (partial year)

Additional adult-use states include Alaska, Arizona, Connecticut, Delaware, Maine, Maryland, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, and Virginia. Delaware and Minnesota enacted legalization through legislation rather than ballot measures, demonstrating growing legislative comfort with reform.

Medical-Only States

Arkansas, Florida, Louisiana, Mississippi, North Dakota, Oklahoma, Pennsylvania, South Dakota, Utah, West Virginia, and several others maintain medical programs without adult-use legalization. Florida's medical program serves over 800,000 registered patients, the largest in the nation, with a adult-use ballot measure expected in 2026. Texas permits low-THC medical cannabis for specific conditions through its Compassionate Use Program, representing one of the most restrictive medical frameworks.

Prohibition States

Idaho, Kansas, Nebraska, South Carolina, Tennessee, Wisconsin, and Wyoming maintain full prohibition of cannabis for any purpose. These states have resisted medical legalization despite neighboring states' programs, creating enforcement challenges as residents cross borders to access legal products. Kansas and Nebraska sued Colorado in 2014 claiming that legalization increased cross-border trafficking, but the Supreme Court declined to hear the case.

Market and Business Implications

The U.S. cannabis industry generated $30 billion in sales in 2024, supporting approximately 400,000 jobs, but operates under structural disadvantages that federal rescheduling or legalization would eliminate. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings operate hundreds of dispensaries across multiple states but cannot consolidate operations or access capital markets efficiently due to federal prohibition.

Section 280E Tax Burden

Cannabis businesses paid an estimated $3 billion in additional federal taxes in 2024 due to 280E, which prohibits deducting rent, salaries, marketing, and other ordinary expenses. Companies can deduct only cost of goods sold, resulting in effective tax rates of 70 percent or higher on gross profit. A vertically integrated operator with $10 million in revenue, $6 million in cost of goods sold, and $3 million in operating expenses would pay federal tax on $4 million rather than $1 million in net income, adding approximately $1 million in tax liability. Rescheduling to Schedule III would eliminate this burden, immediately improving profitability across the industry.

Banking and Capital Access

Fewer than 700 of the nation's 4,800 federally insured banks and credit unions serve cannabis businesses, according to FinCEN data. Most operators rely on credit unions or state-chartered banks, paying premium fees for basic services. The lack of banking access forces cash operations that create security risks and complicate tax compliance. Cannabis companies cannot list on the New York Stock Exchange or Nasdaq, instead trading on the Canadian Securities Exchange or over-the-counter markets with limited liquidity. Institutional investors largely avoid the sector due to federal illegality, constraining growth capital.

Interstate Commerce Prohibition

Federal prohibition prevents interstate cannabis commerce, forcing each state to maintain a closed-loop system from cultivation through retail. California produces far more cannabis than its market consumes, with wholesale prices falling to $300-500 per pound in 2024, while East Coast markets face supply constraints and prices of $2,000-3,000 per pound. Interstate commerce would allow efficient production in low-cost regions, reduce prices for consumers, and improve profitability for producers—but remains illegal even between adult-use states. The state-trigger bill would not directly authorize interstate commerce, which would require descheduling or specific congressional authorization.

Impact on Multi-State Operators

Large MSOs have pursued growth through acquisitions despite federal constraints, but cannot complete traditional mergers due to banking limitations. Deals are structured as all-cash transactions or complex share exchanges. Curaleaf operates 150 dispensaries across 18 states with $1.3 billion in 2024 revenue but cannot optimize supply chains across state lines. Trulieve dominates Florida with 60 percent market share but faces regulatory barriers to expanding that model nationally. The industry has consolidated significantly since 2020, with the top 10 operators controlling approximately 35 percent of national sales, but fragmentation remains far higher than in comparable industries.

Pharmaceutical Industry Positioning

Major pharmaceutical companies have largely avoided cannabis due to federal prohibition and the difficulty of patenting plant-derived products. GW Pharmaceuticals, acquired by Jazz Pharmaceuticals for $7.2 billion in 2021, developed Epidiolex through the FDA approval process, demonstrating a pathway for pharmaceutical-grade cannabis products. Schedule III status would ease research restrictions and potentially accelerate pharmaceutical development, though whole-plant cannabis would remain distinct from FDA-approved medications. Some analysts project that federal legalization could attract pharmaceutical investment exceeding $10 billion within five years.

What Experts Say

Drug policy researchers have long advocated for aligning federal law with state practice to reduce legal uncertainty and improve public health outcomes. According to the Drug Policy Alliance, the current federal-state conflict undermines respect for law and diverts enforcement resources from serious crimes. The organization has supported rescheduling as an interim step but argues that full descheduling is necessary to eliminate criminal penalties and allow states to regulate cannabis like alcohol. The Marijuana Policy Project has emphasized that rescheduling to Schedule III would provide significant tax relief and research benefits but would not resolve banking access or interstate commerce issues. The organization supports the state-trigger approach as a mechanism to force federal action that has stalled despite overwhelming public support, with polling consistently showing 70 percent of Americans favor legalization. Constitutional law scholars have noted that the proposed state-trigger mechanism raises novel federalism questions about whether Congress can delegate scheduling authority to state legislatures. The Constitution grants Congress power to regulate interstate commerce, and the Controlled Substances Act represents an exercise of that power. Allowing states to effectively control federal scheduling through their own legislative choices could be characterized as an unconstitutional delegation or, alternatively, as Congress choosing to condition federal policy on state actions—a practice with precedent in areas like Medicaid expansion and environmental regulation. Medical researchers have emphasized that Schedule I status has severely constrained cannabis research for decades. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has stated that rescheduling would facilitate research into therapeutic applications and risks, though she has cautioned that cannabis is not harmless and that more data is needed on long-term health effects, particularly for adolescents. The American Medical Association has supported rescheduling to enable research while stopping short of endorsing legalization. Business analysts project that eliminating 280E could increase cannabis industry profitability by 20-30 percent, potentially triggering a wave of consolidation and institutional investment. However, they note that continued federal prohibition under Schedule III would maintain banking obstacles and prevent interstate commerce, limiting growth compared to full legalization. The industry's total addressable market could reach $50-75 billion annually if federal barriers were fully removed, according to investment research firms.

What's Next

The state-trigger bill faces significant obstacles in Congress, where cannabis reform has repeatedly stalled despite House passage of legalization measures. The legislation will require committee hearings, markup, and floor votes in both chambers. Republican leadership has historically opposed legalization, though some conservative members support states' rights arguments. The bill's fate likely depends on whether it can attract bipartisan support by framing the issue as federalism rather than drug policy.

Pending Schedule III Rescheduling

The DEA's proposed marijuana rescheduling to Schedule III remains the most immediate potential change to federal policy. The agency must review over 43,000 public comments, address substantive objections, and publish a final rule. Administrative law experts project the final rule could be published in late 2026 or early 2027, though legal challenges are certain. Opponents may argue that the HHS recommendation was inadequate or that marijuana still lacks accepted medical use under the statutory standard. Courts could take years to resolve such challenges.

State Ballot Measures

Florida voters are expected to consider adult-use legalization in November 2026, with polling showing majority support. If approved, Florida would become the largest adult-use market, potentially adding $3-4 billion in annual sales. Pennsylvania, Ohio, and other states are considering medical or adult-use expansions through legislation. Each additional state that legalizes increases pressure on federal policy and moves closer to any threshold the state-trigger bill might establish.

Banking Legislation

The SAFE Banking Act or similar legislation could advance separately from comprehensive reform, providing financial services access without changing cannabis's scheduled status. Senate Banking Committee Chair Sherrod Brown has indicated openness to the measure if coupled with social equity provisions. Banking reform could pass with bipartisan support even if legalization remains politically unfeasible, as it addresses practical problems facing state-legal businesses.

International Developments

Germany launched adult-use legalization in April 2024, joining Canada, Uruguay, and Mexico in permitting recreational cannabis nationally. The United Nations Single Convention on Narcotic Drugs of 1961 requires signatories to limit cannabis to medical and scientific use, creating international law conflicts that the U.S. and other legalizing nations have navigated through various interpretations. U.S. federal legalization would further erode the international prohibition framework and potentially encourage additional countries to reform their policies.

Timeline and Decision Points

• Late 2026: DEA expected to publish final rule on Schedule III rescheduling
• November 2026: Florida adult-use ballot measure
• 2027: Legal challenges to rescheduling likely reach federal courts
• 2027-2028: State-trigger bill committee consideration if it gains momentum
• 2028: Presidential election could shift federal enforcement priorities

Further Reading

• Controlled Substances Act, 21 U.S.C. §§ 801-904 — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling (May 2024) — https://www.federalregister.gov/
• HHS Recommendation to Reschedule Marijuana (August 2023) — https://www.hhs.gov/
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• National Conference of State Legislatures Cannabis Overview — https://www.ncsl.org/health/cannabis-overview
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" — https://crsreports.congress.gov/
• Drug Policy Alliance Federal Policy Resources — https://drugpolicy.org/
• NORML Federal Legislation Tracker — https://norml.org/laws/
• Marijuana Moment Congressional Bill Coverage — https://www.marijuanamoment.net/